Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tarlatamab in Small Cell Lung Cancer (DeLLphi-300)
NCT03319940Phase 1Active, not recruiting
- Sponsor
- Amgen
- Start
- Dec 2017
- Primary completion
- Dec 2027
- Modality
- Bispecific Antibodies, T-cell Engagers
- Countries
- 13
01
Overview
Phase 1, open-label trial of tarlatamab in Small Cell Lung Cancer (SCLC) (6 arms), sponsored by Amgen. Primary endpoints: Dose Limiting Toxicities at 6 months, Treatment-Emergent Adverse Events at 4 years and 5 more. Started Dec 2017; status: active, not recruiting.
02
Drugs
tarlatamab
03
Conditions
Small Cell Lung Cancer (SCLC)
Beyond the preview
Go deeper on NCT03319940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03319940.